ILiAD is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Founded by Keith Rubin in 2012, ILiAD Biotechnologies is backed by investors that include JEMS Venture Capital, Network-1, SDS Capital Partners, and Seedlings Life Science Ventures and is headquartered in New York.